Prof. Fan's research has made groundbreaking contributions to the development of micro- and nanofluidics devices for single-cell and spatial omics, particularly in cancer research, immunology, and immuno-oncology. These technologies, along with the automation systems, were commercialized by IsoPlexis (now Bruker) and are used by over 100 cancer centers and pharmaceutical companies — including all top 15 major global pharmaceutical firms — to evaluate cancer immunotherapies. In the emerging field of spatial omics, Prof. Fan reported the first spatial multi-omics and spatial epigenome sequencing technologies, commercially available through AtlasXomics. He further developed Patho-DBiT, the first clinical pathology-compatible spatial total RNA transcriptome sequencing technology, holding immense potential to revolutionize clinical diagnostics and precision medicine. Dr. Fan's innovations have led to the founding of multiple biotech companies, including IsoPlexis, Singleron Biotechnologies, and AtlasXomics, where he serves as co-founder and scientific advisor. He has also served on the Scientific Advisory Board of Bio-Techne (NASDAQ: TECH) and chaired the Advisory Board of BioPath. His contributions have been recognized with numerous awards, including the NCI Howard Temin Career Transition Award, the NSF CAREER Award, the Packard Fellowship for Science and Engineering, and the 2024 BMES CMBE Momentum Award. He has been elected to AIMBE, CASE, and the National Academy of Inventors.

Prof. Mason and his lab develop and deploy computational and experimental methodologies to identify the functional genetic elements of the human genome and metagenome. Research spans three main areas: clinical genetics, including molecular profiling of aggressive cancers, unusual diseases, and astronauts; computational biology, including new biochemical and computational techniques in DNA/RNA sequencing and base modifications; and genome engineering for new cell, genome, and microbiome modifications. Prof. Mason is Director of the Aerospace Medicine Biobank and Founder of the MetaSUB Consortium and BioAstra. He is co-founder and global director at Biotia, and author of The Next 500 Years: Engineering Life to Reach New Worlds and The Age of Prediction. He has won the NIH's Transformative R01 Award, the NASA Group Achievement Award, the ISS R&D Award, and the CDC Honor Award for Standardization of Clinical Testing, among others. He has been named one of the "Brilliant Ten" Scientists by Popular Science, featured as a TEDMED speaker, and called "The Genius of Genetics" by 92Y. He is an inventor on four patents and four FDA-authorized diagnostic tests, has co-founded 12 biotechnology companies, and serves as an advisor to 31 others.

Prof. Lappalainen is a leader in human functional genomics with a background in systems genetics and the integration of large-scale human population data with CRISPR-based experimental perturbations. Her research focuses on developing advanced computational methods to map genetic effects on molecular traits and extract insights from multi-omic data, both from human populations and from single-cell data. The ultimate goal is to uncover the functional genetic architecture of human disease and translate these findings into an understanding of the molecular processes underlying disease risk. As Director of SciLifeLab's National Genomics Infrastructure in Sweden, she is a key driver of the national genomics technology and applications strategy, overseeing a major genomics infrastructure with partners nationally and internationally. Prof. Lappalainen has held leadership and key contributing roles in major research consortia, including the GTEx and GEUVADIS Consortia, championing the creation of shared, open-access data resources for the scientific community. Via her roles in national and international research community initiatives, she has been part of shaping the vision for human genetics and genomics, and serves as an advisor to multiple institutes, programs, and companies in the fields of genomics and biotechnology.

Prof. Heyn is an expert in genomics with a background in single-cell and spatial sequencing technologies as well as genome-wide genomics profiling approaches. His research activities focus on translational and clinical science with a strong focus on immune-based diagnostic and therapeutic strategies. His group at CNAG joins biotechnology with computational biology to establish best practices in single-cell and spatial research, combining translational research and R&D activities with a focus on immuno-oncology and immune-mediated inflammatory diseases. Prof. Heyn is a member of the Human Cell Atlas (HCA) project, with projects to generate atlases of human immune cells, the kidney, and the pancreas. He co-chairs the Spatial Taskforce, the Industry Partnership Program, and the Standards and Technology working group to scout, benchmark, and scale emerging technologies for the HCA and genomics community. As co-founder and Chief Scientific Officer of Omniscope, he brings high-resolution profiling technologies to clinical application, developing advanced diagnostics and therapeutics tools. Omniscope is a Systems Immunology company providing solutions to detect diseases for interceptive medicine and to develop next-generation cell therapies.

Dr. Villani is a leader in genomics and systems immunology, pioneering the use of single-cell and spatial multi-omics technologies together with advanced computational frameworks to deepen our understanding of the human immune system. Her research is guided by a central vision: to build a comprehensive, high-resolution map of human immunity that captures cellular diversity, functional states, and regulatory principles across tissues, health and disease, human populations, and the lifespan. Collectively, her work enables the study and modeling of the human immune system as a function of healthy and inflammatory states, disease progression, and treatment response — with the long-term goal of translating these insights into mechanism-driven, personalized immunomodulatory therapies. A strong advocate for open science and global collaboration, Dr. Villani holds multiple leadership roles within the Human Cell Atlas (HCA), an international consortium of over 3,700 scientists across 104 countries. She serves as Co–Vice Chair of the HCA Organizing Committee, co-chairs the HCA Data Ecosystem Oversight group, and co-leads the HCA Immune Bionetwork, which aims to generate a detailed, cross-tissue map of the human immune system across diverse populations. Through these roles, she helps shape the scientific, ethical, technological, and analytical frameworks required to build a shared, interoperable reference of the human body.

Prof. Kulasinghe has pioneered spatial transcriptomics, proteomics, and interactomics in the Asia-Pacific region, contributing to world-first studies in lung cancer, head and neck cancer, and tissue atlasing studies of infectious diseases across pandemics. His research aims to understand the underlying pathobiology by using integrative multi-omics approaches. As Founding Scientific Director of the Queensland Spatial Biology Centre at the Wesley Research Institute, he leads a nationally significant spatial biology infrastructure. His research is supported by the MRFF, NHMRC, US DoD, Cancer Australia, Cure Cancer, and numerous hospital and philanthropic organisations, reflecting the broad translational impact of his work across multiple cancer types and infectious disease contexts.

Prof. Banovich leads transformative research on how genetic and molecular variation contributes to human disease. By leveraging advanced genomic technologies, including single-cell RNA sequencing and spatial transcriptomics, his team maps genetic and molecular changes at single-cell resolution, providing critical insights into disease initiation and progression. This work aims to identify novel biomarkers and therapeutic targets to improve patient outcomes, with a strong focus on chronic lung diseases alongside expertise across multiple disease areas. His laboratory employs multi-omics approaches to understand how human genetic variation shapes complex disease onset, progression, and treatment response. The lab also develops innovative experimental and computational methods to expand the capabilities of single-cell and spatial transcriptomics, including pioneering tissue-processing workflows. As Founding Director of TGen's Center for Spatial Multiomics (COSMO), Prof. Banovich oversees the strategic direction and management of TGen's spatial omics infrastructure. He has led the onboarding of multiple spatial platforms, often among the first in the United States — and globally — to access these emerging technologies. Prof. Banovich is also an active member of the Human Cell Atlas Lung Biological Network and the NHLBI LungMap Consortium.

Prof. Ziegenhain is a biotechnologist focusing on emerging single-cell sequencing technologies. He has developed several single-cell methods — including Smart-seq3 — and related computational tools to study transcriptional processes in human cells at population scale. As Group Leader at the Karolinska Institutet, his research ranges from technology development in both experimental multi-omic assays and computational and statistical frameworks to biomedical questions. His team investigates transcriptional responses and alternative splicing patterns in cancers and interacting immune cells. Prof. Ziegenhain is also co-founder and CEO of Xpress Genomics, a sequencing technology company committed to providing highest-quality single-cell RNA sequencing tools built upon discoveries made in collaboration with Prof. Sandberg at KI. Xpress Genomics delivers cutting-edge technologies to researchers at high scale, positioning itself as a disruptive player in the NGS service provider space.

Prof. Prabhakar's research group uses cutting-edge spatial and single-cell technologies to generate massive omics datasets from clinical samples, and develops novel algorithms to identify actionable biomarkers and disease mechanisms. He leads the 5-nation effort to build the first multi-national single-cell atlas of human immune diversity, which revealed unexpectedly large differences between ethnicities. He has led two translationally focused spatial omics consortia, including TISHUMAP, which uses multimodal AI to combine subcellular-resolution spatial RNA profiling with tissue imaging and matched clinical metadata to identify new diagnostic and targetable biomarkers for multiple cancers and fibroinflammatory conditions. Prof. Prabhakar serves on the international Human Cell Atlas consortium's Organizing and Executive Committees, as well as the HCA-Asia Steering Committee. He founded the Singapore Single Cell Network and co-leads the HCA's Genetic Diversity Network and Data Ecosystem Oversight group. He has led multiple research collaborations with biotech and pharma industry partners.

Prof. Powell is an internationally recognised leader in human genomics, with pioneering contributions to population-scale genetics, single-cell and multi-omic sequencing, and AI-enabled functional biology. His research focuses on understanding causal disease mechanisms and accelerating therapeutic discovery through scalable, next-generation genomic platform systems. At the Garvan Institute and UNSW, his programs integrate large human cohorts, advanced cellular models, and machine learning to map regulatory mechanisms across complex diseases. His teams unite biotechnology, computational biology, and stem-cell engineering to deliver discovery pipelines that support translational and clinical innovation. He is a leading contributor to major international initiatives, including the Human Cell Atlas Diversity project, large-scale regulatory mapping efforts, and multiple global consortia shaping the future of precision genomics. His work frequently intersects with industry in genomics technologies and AI-driven drug discovery. As co-founder of Celltellus Labs, Prof. Powell advances stem-cell and multi-omic platforms for precision drug discovery, integrating large-scale functional genomics with cutting-edge machine learning to uncover actionable targets, validate mechanisms, and generate high-confidence translational evidence.